We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


ARKRAY develops, manufactures, and distributes sample test devices, diagnostic regents, and diagnostic support tools ... read more Featured Products: More products

Download Mobile App

PT/INR Monitoring System Uses Novel Clot-Detection Technology to Deliver Results at POC

By LabMedica International staff writers
Posted on 13 Jul 2023
Print article
Image: Assure PT Care is a point-of-care test that measures the time it takes blood to clot (Photo courtesy of CoaguSense)
Image: Assure PT Care is a point-of-care test that measures the time it takes blood to clot (Photo courtesy of CoaguSense)

For precise determination of prothrombin time, medical professionals and researchers often rely on either the World Health Organization (WHO) mechanical tilt tube technique or the Fibrometer. Both methods utilize a mechanical process to directly identify clot formation but can be complex to perform. Now, an advanced PT/INR Monitoring System marks a significant breakthrough in point-of-care prothrombin time monitoring technology, thanks to its miniaturization and simplification of the direct mechanical clot detection process.

ARKRAY USA, Inc. (Kyoto, Japan), in a strategic partnership with CoaguSense, Inc. (Fremont, CA, USA), has launched the Assure PT Care PT/INR Monitoring System. ARKRAY USA is the sole distributor of Assure PT Care, a point-of-care test that measures the clotting time of blood utilizing a patented micromechanical system. The system's results are comparable to those of the gold-standard WHO tilt-tube method and are reported in PT seconds and INR with the highest levels of accuracy and precision. Instant results are crucial for effectively monitoring patients on anticoagulation therapy, enabling optimal care decisions. The Assure PT Care system, which is wireless, enhances operational efficiency for PT/INR testing and offers immediate results, facilitating prompt treatment decisions. It is certified for professional use in a CLIA-waived setting and offers the benefits of being compact and easy to use.

"ARKRAY is committed to offering reliable and cost-effective solutions to our long-term care customers," said Tadashi Inoue, Chief Executive Officer of ARKRAY USA. "We are excited to broaden and diversify our product offering with Assure PT Care to continue serving our customers with a brand they know and trust for reliability, quality, and excellent service."

Related Links:
CoaguSense, Inc. 

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article


Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The new tests seek to detect mutant DNA in blood samples, indicating the presence of cancer cells (Photo courtesy of Christian Stolte/Weill Cornell)

Advanced Liquid Biopsy Technology Detects Cancer Earlier Than Conventional Methods

Liquid biopsy technology has yet to fully deliver on its significant potential. Traditional methods have focused on a narrow range of cancer-associated mutations that are often present in such low quantities... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.